Case Report: Type II Bartter syndrome with a novel KCNJ1 variant in a premature neonate presenting with features of salt-wasting congenital adrenal crisis and pseudo-hypoaldosteronism
Authors:
Open Access
- 24 June 2025
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1550608
Abstract
Introduction: Bartter syndrome (BS) is a rare group of inherited renal tubulopathies. Diagnosis of BS type II is challenging in the neonatal period as its clinical findings and biochemical features may mimic that of adrenal crisis and pseudo-hypoaldosteronism (PHA) initially. Treatment should be instituted immediately for acute adrenal insufficiency as it is a medical emergency, then modified according to available investigation results and treatment response.Case presentation: We describe a premature female neonate with an antenatal history of severe unexplained polyhydramnios, presented with features of adrenal crisis managed with hydrocortisone and fludrocortisone. Initial endocrine investigations excluded salt-wasting congenital adrenal hyperplasia (SW-CAH) and pointed to the diagnosis of PHA with hyperreninemic hyperaldosteronism. Hydrocortisone was gradually weaned off while fludrocortisone was continued for sodium retention effect. Hyperkalemia quickly transited into hypokalemia requiring high potassium requirement. Clinical and biochemical features of BS gradually evolved with polyuria, excessive weight loss, hypochloremic metabolic alkalosis and hypercalciuria at 1 week of age. Urgent trio whole exome sequencing (WES) subsequently confirmed the diagnosis of BS type II where compound heterozygous missense variants were identified in the KCNJ1 gene, one of which was a novel variant. Fludrocortisone was stopped and indomethacin was started with favorable outcomes.Conclusion: Though hypokalemia is the key feature of BS, transient hyperkalemia can occur in the early neonatal period in BS type II. Antenatal history should be enquired thoroughly to look for presence of severe unexplained polyhydramnios. The diagnosis of BS type II should be considered if other biochemical features are present. Genetic tests are important to provide a definite diagnosis and guide subsequent management and genetic counselling.Keywords
This publication has 13 references indexed in Scilit:
- Genetic background of neonatal hypokalemiaPediatric Nephrology, 2024
- Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular DisordersKidney International, 2021
- Congenital Adrenal Hyperplasias Presenting in the Newborn and Young InfantFrontiers in Pediatrics, 2020
- VP32.08: Clinical case of pregnancy and follow‐up of Bartter syndrome (type 2) with a novel mutationUltrasound in Obstetrics & Gynecology, 2020
- Clinical and diagnostic features of Bartter and Gitelman syndromesClinical Kidney Journal, 2017
- Secondary Nephrogenic Diabetes Insipidus as a Complication of Inherited Renal DiseasesNephron Physiology, 2010
- A comprehensive guide to the ROMK potassium channel: form and function in health and diseaseAmerican Journal of Physiology-Renal Physiology, 2009
- A novel mutation in KCNJ1 in a Bartter syndrome case diagnosed as pseudohypoaldosteronismPediatric Nephrology, 2007
- Transient neonatal hyperkalemia in the antenatal (ROMK defective) Bartter syndromeThe Journal of Pediatrics, 2003
- Internal potassium shift in premature infants: Cause of nonoliguric hyperkalemiaThe Journal of Pediatrics, 1995